<?xml version="1.0"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
   <channel>
	  <atom:link href="http://www.realwire.com/rss/?id=120" rel="self" type="application/rss+xml" />
      <title>pharmaceutical-drug development feed from realwire</title>
      <link>http://www.realwire.com/</link>
      <description>Most recent 15 pharmaceutical-drug development articles distributed by realwire</description>
      <language>en-gb</language>
      <lastBuildDate>Sat, 25 May 2013 00:00:01 +0100</lastBuildDate>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs>
      <category>News</category>
      <managingEditor>enquiries@realwire.com (RealWire)</managingEditor>
      <copyright>Copyright (c) 2013 Realwire limited</copyright>
	  <ttl>60</ttl>
      <image>
        <title>pharmaceutical-drug development feed from realwire</title>
        <url>http://www.realwire.com/images/realwireRSS.png</url>
        <link>http://www.realwire.com/</link>
      </image>

      <item>
         <title>Teva welcomes landmark 'victory for patient' in Intellectual Property case</title>
		 <link>http://www.realwire.com/releases/Teva-welcomes-landmark-victory-for-patient-in-Intellectual-Property-case</link>
         <description><![CDATA[LONDON, 30 April 2013 - Teva UK Limited (Teva) has welcomed the judgment of the Court of Appeal today in support of its case against AstraZeneca relating to the validity of the patent covering quetiapine ER (a generic version of Seroquel&#174;). This ruling confirmed the decision of the UK High Court in March 2012 that AstraZeneca's patent was invalid.Seroquel&#174;, an antipsychotic treatment, was launched in its generic form quetiapine by Teva on expiry of the...

Source: RealWire]]></description>
         <pubDate>Tue, 30 Apr 2013 16:02:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Teva-welcomes-landmark-victory-for-patient-in-Intellectual-Property-case</guid>
      </item>
  
      <item>
         <title>Mundipharma strengthens oncology portfolio with strategic collaboration for next generation alkylating agents</title>
		 <link>http://www.realwire.com/releases/Mundipharma-strengthens-oncology-portfolio-with-strategic-collaboration-for-next-generation-alkylating-agents</link>
         <description><![CDATA[- Mundipharma and Northlake International sign deal worth US$84.5 million - Mundipharma will collaborate on the development of NL-101 and receive global (excluding China) commercialization rightsCambridge, UK, 27 November 2012 - Mundipharma International Corporation Limited (Mundipharma) and Northlake International LLC announced today that they have entered into a strategic collaboration agreement to develop structurally novel - next generation alkylating agents for the treatment of haematological malignancies. The agreement grants Mundipharma and its independent associated companies...

Source: RealWire]]></description>
         <pubDate>Tue, 27 Nov 2012 13:10:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Mundipharma-strengthens-oncology-portfolio-with-strategic-collaboration-for-next-generation-alkylating-agents</guid>
      </item>
  
      <item>
         <title>Gut bacteria could cause diabetes</title>
		 <link>http://www.realwire.com/releases/Gut-bacteria-could-cause-diabetes</link>
         <description><![CDATA[GUT BACTERIA AND TYPE 2 DIABETESStudying gut bacteria can reveal a range of human illness. Now, new research shows that the composition of a person's intestinal bacteria could play an important role in the development of type 2 diabetes. These results, from a joint European and Chinese research team, have just been published in the journal Nature.The number of people suffering from type 2 diabetes world-wide has risen rapidly in recent years, and scientists estimate...

Source: RealWire]]></description>
         <pubDate>Thu, 27 Sep 2012 10:30:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Gut-bacteria-could-cause-diabetes</guid>
      </item>
  
      <item>
         <title>Avere Systems Solves VMware Storage Problem at Clinical Stage Biotechnology Company</title>
		 <link>http://www.realwire.com/releases/Avere-Systems-Solves-VMware-Storage-Problem-at-Clinical-Stage-Biotechnology-Company</link>
         <description><![CDATA[FXT Series Edge filers improves 'bursty' VM traffic flow at Concert PharmaceuticalsPITTSBURGH, August 20, 2012 - Avere Systems today announced that Concert Pharmaceuticals Inc., a clinical stage biotechnology company, has implemented its FXT Series Edge filers into its existing storage infrastructure. The Avere Edge filers were chosen to reduce latency and improve performance of applications critical in Concert's mission.Lexington, Mass.-based Concert is dedicated to creating new medicines through its proprietary DCE Platform&#8482; that utilizes the...

Source: RealWire]]></description>
         <pubDate>Mon, 20 Aug 2012 13:30:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Avere-Systems-Solves-VMware-Storage-Problem-at-Clinical-Stage-Biotechnology-Company</guid>
      </item>
  
      <item>
         <title>Study Proves RFID Technology Safe for Use with Biologics</title>
		 <link>http://www.realwire.com/releases/Study-Proves-RFID-Technology-Safe-for-Use-with-Biologics</link>
         <description><![CDATA[Research Report Findings Published in the Parenteral Drug Association Journal Demonstrate that RFID can be Instrumental as ePedigree Laws are EnactedReading, UK July 25, 2012 - Intelleflex, a leading provider of on-demand data visibility solutions for supply chains and asset tracking, supports the findings of a study published by the Parenteral Drug Association (PDA) that RFID technology is both safe and suitable for use in the presence of biologics. The study, "Effects of Radio Frequency...

Source: RealWire]]></description>
         <pubDate>Wed, 25 Jul 2012 12:00:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Study-Proves-RFID-Technology-Safe-for-Use-with-Biologics</guid>
      </item>
  
      <item>
         <title>PRECOS Launches Premium Bespoke Collection of Clinically Relevant Lung In Oncology Models for Drug Discovery</title>
		 <link>http://www.realwire.com/releases/PRECOS-Launches-Premium-Bespoke-Collection-of-Clinically-Relevant-Lung-In-Oncology-Models-for-Drug-Discovery</link>
         <description><![CDATA[NOTTINGHAM, UK (29 May 2012) - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has launched its Lung In ONcology model atlas (LION). LION provides a premium bespoke collection of clinically relevant and validated lung oncology models for in vitro and in vivo drug discovery screening. The models are of interest to leading pharmaceutical and biopharmaceutical companies looking to deliver significantly higher research productivity...

Source: RealWire]]></description>
         <pubDate>Tue, 29 May 2012 16:43:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/PRECOS-Launches-Premium-Bespoke-Collection-of-Clinically-Relevant-Lung-In-Oncology-Models-for-Drug-Discovery</guid>
      </item>
  
      <item>
         <title>Molecular Profiles and GEA Process Engineering Partner to Demonstrate Benefits of New Technology</title>
		 <link>http://www.realwire.com/releases/Molecular-Profiles-and-GEA-Process-Engineering-Partner-to-Demonstrate-Benefits-of-New-Technology</link>
         <description><![CDATA[Early Screening of Solid Dispersions for Developing Poorly Soluble Drugs(Nottingham, 29 May 2012) Molecular Profiles, a leading specialist contract research and manufacturing organisation, announces that it has entered into a strategic collaboration with GEA Process Engineering - the company behind the world-recognized GEA Niro spray drying technology. Using the GEA Niro DRYNETICS&#8482;, single particle spray drying approach, the collaboration will assess early screening of poorly water soluble drugs and polymer compositions for the improvement in...

Source: RealWire]]></description>
         <pubDate>Tue, 29 May 2012 11:38:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Molecular-Profiles-and-GEA-Process-Engineering-Partner-to-Demonstrate-Benefits-of-New-Technology</guid>
      </item>
  
      <item>
         <title>Array BioPharma to Adopt Contract Management Solution from Seal Software Group</title>
		 <link>http://www.realwire.com/releases/Array-BioPharma-to-Adopt-Contract-Management-Solution-from-Seal-Software-Group</link>
         <description><![CDATA[Solution Will Streamline Contract Processes, Help Control Costs and Improve EfficiencyLondon, UK - 18th April 2012 - Seal Software Group, a provider of solutions to discover, capture, extract and manage contracts, today announced that Array BioPharma Inc. has selected Seal Software to help with their drive to boost productivity and improve efficiency through the deployment of Seal's Contract Discovery (cDiscovery) and Contract Management solutions.Array is a biopharmaceutical company focused on the discovery, development and commercialization...

Source: RealWire]]></description>
         <pubDate>Wed, 18 Apr 2012 10:00:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Array-BioPharma-to-Adopt-Contract-Management-Solution-from-Seal-Software-Group</guid>
      </item>
  
      <item>
         <title>Freeze Drying Specialists BTL Announce New Cytotoxic Capability</title>
		 <link>http://www.realwire.com/releases/Freeze-Drying-Specialists-BTL-Announce-New-Cytotoxic-Capability</link>
         <description><![CDATA[Winchester, UK, 11th April 2012: Biopharma Technology Ltd (BTL) have completed construction of a new standalone cleanroom, enabling them to provide freeze drying R&amp;D services for cytotoxic products.Freeze drying is a complex operation and many drug developers outsource development to contract research organisations specialist in this field. However, few CROs with freeze drying expertise have the ability to handle cytotoxic drugs safely.About Cytotoxics Cytotoxic therapies are most commonly used in cancer chemotherapies and work by...

Source: RealWire]]></description>
         <pubDate>Wed, 11 Apr 2012 16:18:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Freeze-Drying-Specialists-BTL-Announce-New-Cytotoxic-Capability</guid>
      </item>
  
      <item>
         <title>Tibco Spotfire Webcast To Show How Spotfire Enables Faster And Smarter Clinical Development</title>
		 <link>http://www.realwire.com/releases/Tibco-Spotfire-Webcast-To-Show-How-Spotfire-Enables-Faster-And-Smarter-Clinical-Development</link>
         <description><![CDATA[Somerville, Mass, March 8, 2012 - TIBCO Software Inc. (NASDAQ: TIBX) today announced it will host a complimentary webcast on Thursday, March 15, 2012 titled "How Leading European Life Science Companies Are Leveraging Spotfire&#174; for Clinical Development."What/When: "How Leading Life Science Companies Are Leveraging Spotfire for Clinical Development" webcast - Thursday, March 15, 2012 at 11:00 a.m. GMT.Join TIBCO Spotfire to learn how leading European life science companies are using TIBCO Spotfire to identify new...

Source: RealWire]]></description>
         <pubDate>Thu, 08 Mar 2012 14:00:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Tibco-Spotfire-Webcast-To-Show-How-Spotfire-Enables-Faster-And-Smarter-Clinical-Development</guid>
      </item>
  
      <item>
         <title>ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients</title>
		 <link>http://www.realwire.com/releases/ERT-and-UCLA-Initiate-Innovative-Pilot-Program-for-Chronically-Ill-Patients</link>
         <description><![CDATA[More than 150 patients with COPD will receive additional health care services to improve their health and lower the costs of long term care.Program will test the benefits of remote monitoring services on a needy and growing population.PHILADELPHIA, February 08, 2012 - ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study in collaboration with UCLA, an...

Source: RealWire]]></description>
         <pubDate>Wed, 08 Feb 2012 16:06:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/ERT-and-UCLA-Initiate-Innovative-Pilot-Program-for-Chronically-Ill-Patients</guid>
      </item>
  
      <item>
         <title>Cambridge Crystallographic Data Centre Advances Solid Form Informatics</title>
		 <link>http://www.realwire.com/releases/Cambridge-Crystallographic-Data-Centre-Advances-Solid-Form-Informatics</link>
         <description><![CDATA[Cambridge, UK, 3rd October 2011 - The Cambridge Crystallographic Data Centre (CCDC) today announced the CSD Solid Form Suite to support pharmaceutical and agrochemical development. Using a knowledge-based approach the Solid Form Suite provides guidance and decision support for form screening and selection, enabling Quality by Design from an early stage. "Solid Form Informatics is all about distilling the vast amount of data available in the Cambridge Structure Database (CSD) into targeted and actionable information...

Source: RealWire]]></description>
         <pubDate>Mon, 03 Oct 2011 10:41:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Cambridge-Crystallographic-Data-Centre-Advances-Solid-Form-Informatics</guid>
      </item>
  
      <item>
         <title>Exco InTouch Secures Growth Investment From Sep</title>
		 <link>http://www.realwire.com/releases/Exco-InTouch-Secures-Growth-Investment-From-Sep</link>
         <description><![CDATA[Mobile patient communication leader to use funds to accelerate growth strategyLONDON, UK - 29 September, 2011 - Leading growth equity and venture capital group Scottish Equity Partners (SEP) has led an initial &#163;3m pound investment in Exco InTouch, the leading provider of mobile patient communication and management solutions for the pharmaceutical and healthcare sector.SEP has taken a minority stake in the company which will use the funds to accelerate its expansion, enabling it to take...

Source: RealWire]]></description>
         <pubDate>Thu, 29 Sep 2011 17:10:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Exco-InTouch-Secures-Growth-Investment-From-Sep</guid>
      </item>
  
      <item>
         <title>First UK Patient Enrolled into Luminous&#8482; Programme &#8211; Novartis&#8217; 30,000 Patient Observational Study in Ophthalmology</title>
		 <link>http://www.realwire.com/releases/First-UK-Patient-Enrolled-into-Luminous-Programme-Novartis-30000-Patient-Observational-Study-in-Ophthalmology</link>
         <description><![CDATA[Luminous, launched today, will provide long-term effectiveness, safety, and patient reported outcome data on Lucentis&#174; (ranibizumab) in 30,000 patients in real-life settings across the worldFrimley, August 22 2011 - Novartis Pharmaceuticals UK Ltd (Novartis) has announced the enrollment of the first UK patient into the Luminous&#8482; programme, which aims to advance the understanding of retinal vascular diseases which cause vision loss, including wet Age-related Macular Degeneration (AMD), visual impairment due to Diabetic Macular Oedema (DMO)...

Source: RealWire]]></description>
         <pubDate>Mon, 22 Aug 2011 08:01:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/First-UK-Patient-Enrolled-into-Luminous-Programme-Novartis-30000-Patient-Observational-Study-in-Ophthalmology</guid>
      </item>
  
      <item>
         <title>Cambridge Technology Company ionscope helps researchers make heart discovery</title>
		 <link>http://www.realwire.com/releases/Cambridge-Technology-Company-ionscope-helps-researchers-make-heart-discovery</link>
         <description><![CDATA[A discovery that may one day help the recovery of some people who have suffered a heart attack has been made with the help of ionscope's SICM equipment.Cambridge UK, Thursday 4 August 2011 - SICM, a high resolution microscopy technique, has been used by a team of researchers to identify a drug that could one day be used to prevent abnormal heart rhythms, or arrhythmia. The study, published in Hepatology[1] this week, was enabled by...

Source: RealWire]]></description>
         <pubDate>Thu, 04 Aug 2011 15:48:00 +0100</pubDate>
		 <guid isPermaLink="true">http://www.realwire.com/releases/Cambridge-Technology-Company-ionscope-helps-researchers-make-heart-discovery</guid>
      </item>
  
   </channel>
</rss>
